Compare · MDLN vs NVNO
MDLN vs NVNO
Side-by-side comparison of Medline Inc. (MDLN) and enVVeno Medical Corporation (NVNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and NVNO operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $46.86B, about 6244.1x NVNO ($7.5M).
- MDLN has been more active in the news (12 items in the past 4 weeks vs 3 for NVNO).
- MDLN has more recent analyst coverage (25 ratings vs 0 for NVNO).
- Company
- Medline Inc.
- enVVeno Medical Corporation
- Price
- $35.64+2.77%
- $10.51-0.38%
- Market cap
- $46.86B
- $7.5M
- 1M return
- -
- +0.00%
- 1Y return
- -
- -66.46%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2018
- News (4w)
- 12
- 3
- Recent ratings
- 25
- 0
enVVeno Medical Corporation
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based devices to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and works as a replacement venous valve to reduce reflux and venous hypertension, as well as to restore proper directional blood flow back to the heart. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Latest MDLN
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.
Latest NVNO
- SEC Form S-3 filed by enVVeno Medical Corporation
- Amendment: SEC Form SCHEDULE 13G/A filed by enVVeno Medical Corporation
- Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments
- enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve
- SEC Form 10-Q filed by enVVeno Medical Corporation
- enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment
- enVVeno Medical Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial
- enVVeno Medical to Present in the Webull Corporate Connect Webinar Series
- Director Duhay Francis sold $1,443 worth of shares (140 units at $10.30) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 2,362 units (SEC Form 4)